Acute-onset Neuropsychiatric Syndrome
📧 Sign up to get email alerts when something new happens for Acute-onset Neuropsychiatric Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Patterns of Neurodevelopmental Disorders
This clinical trial update reports that a Richard Frye-sponsored study on patterns of neurodevelopmental disorders, including autism spectru…
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Open-label Trial of IVIG in Children With PANS [Phase 2]
An open-label Phase 2 trial of intravenous immunoglobulin in children with Pediatric Acute-Onset Neuropsychiatric Syndrome has completed.
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
A University of Wisconsin–Madison clinical trial is recruiting participants to study Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) …
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) [Phase 3]
Phase III study comparing Panzyga to placebo in pediatric acute-onset neuropsychiatric syndrome has completed, with trial results posted.
-
CLINICAL_TRIALS trial_result · 2025-09-12Clinical Trial Update: The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS
A completed trial within the Unhide project evaluating the economic impact of intravenous immunoglobulin (IVIG) treatment for Pediatric Acut…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a full-spectrum medicinal cannabis extract with 0.08% THC (NTI164) for Pediatric Acute-onset Neuropsyc…
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) [Phase 4]
Phase 4 trial update evaluating Octagam 5% in pediatric acute-onset neuropsychiatric syndrome (PANS) and related autoimmune neuropsychiatric…
-
CLINICAL_TRIALS trial_result · 2018-04-10Clinical Trial Update: Antibiotic Treatment Trial for the PANDAS/PANS Phenotype [Phase 2]
Phase 2 trial evaluating antibiotic treatment for the PANS/PANDAS phenotype has completed, with results posted on 2018-04-10. The study also…
-
CLINICAL_TRIALS research · 2016-10-06Clinical Trial Update: Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
This clinical trial update notes ongoing recruitment for a study evaluating neurobiologic, immunologic, and rheumatologic markers in youth w…